Drugs / PVX-410
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03362060 | Dec 2017 → Dec 2026 expected | triple-negative breast carcinoma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02886065 | Mar 2017 → Feb 2027 expected | smoldering plasma cell myeloma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02826434 | Aug 2016 → Dec 2026 expected | breast cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01718899 | Nov 2012 → Jun 2016 | smoldering plasma cell myeloma | OncoPep, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04634747 | Apr 2022 → Apr 2023 | triple-negative breast carcinoma | OncoPep, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PVX-410 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03362060 ↗ |
| Modality | Vaccine | “PVX-410 multipeptide vaccine” PMID 30128502 ↗ Dec 2018 |
| Route | Subcutaneous | “biweekly via subcutaneous injection” PMID 30128502 ↗ Dec 2018 |